Eighty percent of patients with MG have detectable antibodies against muscle nicotinic acetylcholine receptors (AChR) and a minority have autoantibody against muscle-specific tyrosine kinase (MuSK) or low-density lipoprotein receptor-related protein 4 (LRP4) (2). The gene discussed is LRP4; the disease is myasthenia gravis.